Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)

(2017) A. K. Nowak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041)

(2017) H. van Laarhoven et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors

(2017) F. G. De Braud et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

(2009) V Gregorc et al.   BRITISH JOURNAL OF CANCER

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

(2008) Paolo A. Zucali et al.   CANCER

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

(2008) David M. Jackman et al.   CANCER

Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma

(2008) Jacek Jassem et al.   JOURNAL OF CLINICAL ONCOLOGY

Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

(2008) Justin Stebbing et al.   LUNG CANCER